Articles

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Ray KK, Troquay RPT, Visseren FLJ, et al.

First published: January 5, 2023  DOI: 10.1016/S2213-8587(22)00353-9